Evidence map›Paper›PMID 38658471›Full record

ArticleMolecular biotechnology2025

Pan-Cancer Analysis Shows that KIFC2 is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Bladder Cancer.

Helin Zhang, Xingxing Zhang, Yuelin Zhang, Dali Han, Hualan Ha, Biao Zhang, Panfeng Shang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Helin Zhang *The Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China.
Xingxing Zhang *The Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China.
Yuelin ZhangThe Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China.
Dali HanThe Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China.
Hualan HaThe Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China.
Biao ZhangThe Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China.
Panfeng ShangThe Second Hospital & Clinical Medical School, Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730030, Gansu, China. shangpf@lzu.edu.cn.ORCID http://orcid.org/0000-0002-9622-9664
Lanzhou University Second Hospital · CN

Funding

This work was supported by the Medical Innovation and Development Project of Lanzhou University Grant No. lzuyxcx-2022-105
6 · The paper itself

Abstract

KIFC2 plays an important role in prostate cancer progression and chemotherapy resistance, but the mechanism of its involvement in other malignancies remains unclear. Therefore, this study aimed to analyze and validate the mechanism of effect of KIFC2 in multiple tumors. Bioinformatic analysis was performed in conjunction with multiple databases (The Cancer Genome Atlas, Genotype-Tissue Expression Project, Human Protein Atlas, etc.) to fully explore the potential role of KIFC2 within individual tumors and to analyze the correlation with major research components such as prognosis, mutations, and the tumor microenvironment. The expression of KIFC2 demonstrates a significant correlation with the prognosis, clinical phenotype, tumor mutational burden, microsatellite instability, and tumor microenvironment across various malignancies and is associated with the modulation of diverse functional and signaling pathways. The differences in the expression of KIFC2 in the bladder cancer tissues (14 pairs) were statistically significant. The pan-cancer analysis in this study revealed the multifunctionality of KIFC2 in a variety of tumors, indicating a possible prognostic predictor and potential therapeutic target for tumors.

Indexed as

Biomarkers, TumorKinesinsNeoplasmsUrinary Bladder NeoplasmsComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansMaleMicrosatellite InstabilityMutationPrognosisTumor MicroenvironmentBiomarkers, TumorKinesinsBladder cancerKIFC2Pan-CancerPrognosisTumor microenvironment

Identifiers

PMID38658471
OpenAlexW4395068888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.